- Home
- MIRM vs KTTA Comparison
MIRM vs KTTA Comparison
Compare MIRM & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- KTTA
- Stock Information
- Founded
- MIRM 2018
- KTTA 2020
- Country
- MIRM United States
- KTTA United States
- Employees
- MIRM N/A
- KTTA N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- MIRM Health Care
- KTTA Health Care
- Exchange
- MIRM Nasdaq
- KTTA Nasdaq
- Market Cap
- MIRM 1.9B
- KTTA N/A
- IPO Year
- MIRM 2019
- KTTA 2021
- Fundamental
- Price
- MIRM $38.39
- KTTA $1.43
- Analyst Decision
- MIRM Strong Buy
- KTTA
- Analyst Count
- MIRM 11
- KTTA 0
- Target Price
- MIRM $58.55
- KTTA N/A
- AVG Volume (30 Days)
- MIRM 439.1K
- KTTA 5.3M
- Earning Date
- MIRM 05-07-2025
- KTTA 05-13-2025
- Dividend Yield
- MIRM N/A
- KTTA N/A
- EPS Growth
- MIRM N/A
- KTTA N/A
- EPS
- MIRM N/A
- KTTA N/A
- Revenue
- MIRM $336,888,000.00
- KTTA N/A
- Revenue This Year
- MIRM $29.51
- KTTA N/A
- Revenue Next Year
- MIRM $20.27
- KTTA N/A
- P/E Ratio
- MIRM N/A
- KTTA N/A
- Revenue Growth
- MIRM 80.76
- KTTA N/A
- 52 Week Low
- MIRM $23.14
- KTTA $0.92
- 52 Week High
- MIRM $54.23
- KTTA $7.69
- Technical
- Relative Strength Index (RSI)
- MIRM 32.65
- KTTA 54.56
- Support Level
- MIRM $37.83
- KTTA $1.13
- Resistance Level
- MIRM $40.32
- KTTA $1.53
- Average True Range (ATR)
- MIRM 2.47
- KTTA 0.22
- MACD
- MIRM -0.28
- KTTA 0.03
- Stochastic Oscillator
- MIRM 17.20
- KTTA 30.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.